NewGene, a UK-based molecular diagnostics startup, could soon be one of the first European laboratories to provide clinical genetic tests on 454's sequencing platform.

Toward the end of this year or in early 2010, the Newcastle upon Tyne-based company plans to offer the UK's National Health Service and other clients full-gene sequencing tests for several genetic conditions using Roche's 454 Genome Sequencer FLX. It expects to offer these tests at a lower cost and with a faster turnaround than existing providers using Sanger sequencing, NewGene said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.